Stem Cell-Derived Cardiomyocyte-Like Cells in Myocardial Regeneration.

cardiomyocytes cell programming myocardial ischemia myocardial regeneration regenerative cardiology stem cell therapy

Journal

Tissue engineering. Part B, Reviews
ISSN: 1937-3376
Titre abrégé: Tissue Eng Part B Rev
Pays: United States
ID NLM: 101466660

Informations de publication

Date de publication:
04 Jul 2023
Historique:
pubmed: 9 6 2023
medline: 9 6 2023
entrez: 9 6 2023
Statut: aheadofprint

Résumé

Myocardial infarction results in the significant loss of cardiomyocytes (CMs) due to the ischemic injury following coronary occlusion leading to impaired contractility, fibrosis, and ultimately heart failure. Stem cell therapy emerged as a promising regenerative strategy to replenish the otherwise terminally differentiated CM to restore cardiac function. Multiple strategies have been applied to successfully differentiate diverse stem cell populations into CM-like phenotypes characterized by the expression status of signature biomarkers and observable spontaneous contractions. This article discusses the current understanding and applications of various stem cell phenotypes to drive the differentiation machinery toward CM-like lineage. Impact Statement Ischemic heart disease (IHD) extensively affects a large proportion of the population worldwide. Unfortunately, current treatments for IHD are insufficient to restore cardiac effectiveness and functionality. A growing field in regenerative cardiology explores the potential for stem cell therapy following cardiovascular ischemic episodes. The thorough understanding regarding the potential and shortcomings of translational approaches to drive versatile stem cells to cardiomyocyte lineage paves the way for multiple opportunities for next-generation cardiac management.

Identifiants

pubmed: 37294202
doi: 10.1089/ten.TEB.2023.0049
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Pauline Cheng (P)

Department of Translational Research, Western University of Health Sciences, Pomona, California, USA.

Ahmad Rashad (A)

Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, California, USA.

Ankit Gangrade (A)

Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, California, USA.

Natan Roberto de Barros (NR)

Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, California, USA.

Ali Khademhosseini (A)

Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, California, USA.

Jonathan Tam (J)

Department of Translational Research, Western University of Health Sciences, Pomona, California, USA.

Padmini Varadarajan (P)

University of California Riverside School of Medicine, Riverside, California, USA.

Devendra K Agrawal (DK)

Department of Translational Research, Western University of Health Sciences, Pomona, California, USA.

Finosh G Thankam (FG)

Department of Translational Research, Western University of Health Sciences, Pomona, California, USA.

Classifications MeSH